SG
HZNP

Stonnington Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stonnington Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$235K Hold
2,121
– – 0.06% 218
2022
Q4 		$240K Buy
+2,121
New +$176K 0.07% 183
2022
Q2 		– Sell
-2,121
Closed -$239K – 256
2022
Q1 		$239K Sell
2,121
-500
-19% -$48.7K 0.06% 214
2021
Q4 		$252K Buy
2,621
+200
+8% +$21.8K 0.05% 217
2021
Q3 		$275K Buy
2,421
+100
+4% +$10.4K 0.06% 221
2021
Q2 		$215K Hold
2,321
– – 0.05% 256
2021
Q1 		$201K Buy
+2,321
New +$196K 0.05% 246

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stonnington Group's HZNP Position: Q1 2023 in Review

Stonnington Group held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q1 2023 at 2,121 shares worth $235K. The position accounts for 0.06% of the portfolio, ranked #218.

Stonnington Group first reported a position in HZNP in Q1 2021 and has held it in 7 quarters since. The position peaked at $275K in Q3 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Stonnington Group held 2,121 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $235K as of Q1 2023.
  • Stonnington Group left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q1 2023.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.06% of Stonnington Group's portfolio in Q1 2023, its #218 holding.
  • Stonnington Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and has held it in 7 quarters since.
  • Stonnington Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $275K in Q3 2021.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.